Abstracts tagged "Rituximab"

Abstract Number: 1724 • 2018 ACR/ARHP Annual Meeting
Effectiveness and Safety of Rituximab for the Treatment of Refractory Systemic Sclerosis Associated Calcinosis: A Case Series
Francisco Javier Narváez¹, Juan Pablo Pirola², Judit Lluch³, Pablo Juárez³, Isabel Morales³ and Joan Miquel Nolla³, ¹Rheumatology Department, Hospital de Bellvitge. Barcelona. Spain, L’Hospitalet de Llobregat, Spain, ²Rheumatology, Hospital Privado Centro Médico de Córdoba, Cordoba, Argentina, ³Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: To analyze the effectiveness and safety of rituximab (RTX) for the treatment of refractory systemic sclerosis (SSc)–associated calcinosis. Methods: We undertook an observational study…
Abstract Number: 547 • 2017 ACR/ARHP Annual Meeting
Long-Term Risk of Serious Infections in Patients with Rheumatoid Arthritis Treated with Rituximab: 5 Year Data from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis
Diederik De Cock¹, Lianne Kearsley-Fleet¹, Lucía Silva Fernández², Mark Lunt¹, Kath Watson¹, Deborah P.M. Symmons^1,3 and Kimme L. Hyrich^1,3, ¹Arthritis Research UK Centre for Epidemiology, University of Manchester, Manchester Academic Health Science Centre, Manchester, United Kingdom, ²Arthritis Research UK Centre for Epidemiology, Centre for Musculoskeletal Research, Manchester Academic Health Science Centre, The University of Manchester, Manchester, United Kingdom, ³National Institute of Health Research Manchester Musculoskeletal Biomedical Research Centre, Central Manchester NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose: In the United Kingdom (UK), rituximab (RTX) or a second tumour necrosis factor inhibitor (TNFi) are both permitted treatment options for patients with rheumatoid…
Abstract Number: 2167 • 2017 ACR/ARHP Annual Meeting
Efficacy and Safety of Rituximab in Anti-Synthetase Positive and Negative Patients with Idiopathic Inflammatory Myopathy– a Registry-Based Study
Valérie Leclair, Maryam Dastmalchi, Angeles Shunashy Galindo-Feria and Ingrid E. Lundberg, Department of Medicine, Rheumatology Unit, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden
Background/Purpose: Rituximab (RTX) in idiopathic inflammatory myopathies (IIM) failed to show efficacy in the placebo-controlled Rituximab in Myositis (RIM) trial. However, post hoc analyses indicated…
Abstract Number: 2567 • 2017 ACR/ARHP Annual Meeting
Type I IFN Blockade Restores Normal Transitional B Cell Development Post-Anti-CD20 Depletion
Jennie Hamilton¹, Qi Wu², PingAr Yang³, Bao Luo⁴, Shanrun Liu⁵, Huixian Hong⁶, Jun Li⁷, Hui-Chen Hsu² and John D. Mountz⁸, ¹Medicine/Division of Clinical Immunology and Rhematology, University of Alabama at Birmingham, Birmingham, AL, ²Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ³Department of Medicine, Clinical Immunology & Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Division of Clinical Immunology and Rheumatology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁵Biochemistry & Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, ⁶University of Alabama at Birmingham， Division of Clinical Immunology and Rheumatology, Department of Medicine, Birmingham, AL, ⁷Medicine, University of Alabama at Birmingham, Birmingham, AL, ⁸University of Alabama at Birmingham, Department of Medicine, Birmingham, AL
Background/Purpose: Application of B cell depletion therapy (BCDT) for treatment of SLE has shown promise in some patients, but some patients exhibit disease relapses. Anti-type…
Abstract Number: 2614 • 2016 ACR/ARHP Annual Meeting
Similar Rates of Death, Serious Infections, Cancers, Major Cardiovascular Events in Patients Treated with Abatacept, Rituximab and Tocilizumab: Long-Term Registry Data in 4498 Patients with Rheumatoid Arthritis
Jacques-Eric Gottenberg¹, Jacques Morel^2,3, Arnaud Constantin⁴, Thomas Bardin⁵, Alain Cantagrel^6,7, Bernard Combe⁸, Maxime Dougados^9,10, Rene-Marc Flipo¹¹, Alain Saraux¹², Thierry Schaeverbeke¹³, Jean Sibilia¹⁴, Martin Soubrier¹⁵, Olivier Vittecoq¹⁶, Elodie Perrodeau¹⁷, Philippe Ravaud¹⁸, Xavier Mariette¹⁹ and on behalf of the French Society of Rheumatology and of all the investigators participating to the AIR, ORA and REGATE registries, ¹Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ²Rheumatology, Department of Rheumatology, Montpellier University Hospital, Montpellier, France, ³Immuno-Rheumatology, University Hospital of Lapeyronie, University Montpellier 1, Montpellier, France, ⁴Rheumatology, CHU Purpan - Hopital Pierre-Paul Riquet, Toulouse, France, ⁵Service de Rhumatologie. Centre Viggo Petersen. Hôpital Lariboisière, Paris, France, ⁶Rheumatology, INSERM CNRS UMR 1043, Paul Sabatier University Toulouse, Purpan Teaching Hospital, Toulouse, France, ⁷Rheumatology, Purpan University Hospital, Toulouse Cedex 9, France, ⁸Département Rhumatologie, Hôpital Lapeyronie, Montpellier, France, ⁹Rheumatology, Paris Descartes University, Paris, France, ¹⁰René Descartes University and Hôpital Cochin, Paris, France, ¹¹Rheumatology, Hopital R Salengro CHRU, Lille, France, ¹²Rheumatology, Brest University Hospital, Brest, France, ¹³Rheumatology, CHU Bordeaux, Bordeaux, France, ¹⁴Department of Rheumatology, Strasbourg University Hospital, Strasbourg, France, ¹⁵Rheumatology, Department of Rheumatology, CHU Gabriel Montpied, Clermont-Ferrand, France, ¹⁶Rheumatology, Rouen University Hospital &INSERM U905, Rouen, France, ¹⁷Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France, ¹⁸Epidemiology, Hotel Dieu, PARIS, France, ¹⁹Rheumatology, Rheumatology department, Bicetre Hospital, Paris-Sud University, Le Kremlin Bicetre, France
Background/Purpose: Assessment of safety in randomized controlled trials is limited by trial durations, and selection of patients with few or now comorbidities. Such limitations can…
Abstract Number: 886 • 2015 ACR/ARHP Annual Meeting
Rituximab As a Cyclophosphimide Sparing Agent for Patients with Multi-Relapsing Antineutrophil Cytoplasmic Antibody Associated Small Vessel Vasculitis
Sophia Lionaki¹, George Fragoulis², Aliki Venetsanopoulou², Panayiotis Vlachoyiannopoulos², John Boletis¹, Haralampos M. Moutsopoulos² and Athanasios G. Tzioufas², ¹Nephrology, Laiko Hospital, Department of Nephrology, Athens, Greece, ²Pathophysiology, School of Medicine, National University of Athens, Athens, Greece
Background/Purpose: To evaluate the long term outcomes, of patients with multi-relapsing Antineutrophil Cytoplasmic Antibody (ANCA) associated Vasculitis (AAV), who received induction therapy with a rituximab…
Abstract Number: 1385 • 2015 ACR/ARHP Annual Meeting
Efficacy and Tolerance of Rituximab in IgG4-Related Disease: A Retrospective Multicentric Study in 24 Patients
Mikael Ebbo¹, Aurélie Grados¹, Maxime Samson², Clarisse Carra-Dallière³, Agnieszka Pozdzik⁴, Pierre Labauge³, Sylvain Palat⁵, Jean-Marie Berthelot⁶, Jean-Loup Pennaforte⁷, Alain Wynckel⁸, Celine Lebas⁹, Thomas Quémeneur¹⁰, Karine Dahan¹¹, Jean-Jacques Boffa¹¹, Bertrand Godeau¹², Nicolas Limal¹², Franck Carbonnel¹³, Anne Herber¹⁴, Gaëlle Leroux¹⁵, Patrice Cacoub¹⁶, Alexis Mathian¹⁷, Eric Hachulla¹⁸, Nathalie Costedoat-Chalumeau¹⁹, Jean-Robert Harle²⁰ and Nicolas Schleinitz¹, ¹Internal Medicine, Aix-Marseille Université, AP-HM, Marseille, France, ²Department of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France, ³Neurology, CHRU de Montpellier, Montpellier, France, ⁴Nephrology, Erasme Hospital, Cliniques Universitaires de Bruxelles, Bruxelles, Belgium, ⁵Service de Medecine Interne, CHU limoges, Limoges, France, ⁶Rhumatologie, CHU Nantes, Nantes, France, ⁷Internal Medicine, CHU de Reims, Reins, France, ⁸Nephrolohy, CHU de Reims, Reims, France, ⁹Nephrology, CHRU de Lille, Lille, France, ¹⁰CH Valenciennes, Valenciennes, France, ¹¹Nephrology, Tenon Hospital, Paris, France, ¹²Internal Medicine, Mondor Hospital, Creteil, France, ¹³Gastro-enterology, CHU Bicêtre, Le Kremlin Bicêtre, France, ¹⁴Gastro-enterology, CH de Chartres, Chartres, France, ¹⁵Department of Internal Medicine 2. Referal center for SLE/APS, CHU Pitié-Salpêtrière, Paris, France, ¹⁶Internal Medicine Department, University Hospital “Pitié-Salpêtrière”, “Pierre et Marie Curie Paris VI” University, Paris, France, ¹⁷Internal Medecine Department, Pitie-Salpetriere Hospital, Paris, France, ¹⁸FAI²R, Hôpital Claude Huriez, CHRU Lille, LILLE, France, ¹⁹Internal Medicine Department, Cochin Hospital, “René-Descartes Paris V” University, Paris, France, ²⁰Internal Medicine, Aix-Marseille Université, APHM, Marseille, France
Background/Purpose: IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition with characteristic histopathological lesions. Nearly all anatomic sites can be involved with a risk of organ…
Abstract Number: 2913 • 2015 ACR/ARHP Annual Meeting
Intensified Treatment of B Lymphocyte Depletion (ITBLD) without Immunosuppressive Maintenance Treatment As a Rescue Therapy in Refractory Lupus Nephritis (LN): A 4-Year Observation
Dario Roccatello¹, Savino Sciascia², Daniela Rossi¹, Carla Naretto³, Simone Baldovino³, Mirella Alpa³, Ilaria Salussola³ and Vittorio Modena³, ¹Department of Medicine and Experimental Oncology, CMID - Center of Research of Immunopathology and Rare Diseases, Turin, Italy, ²Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ³CMID, Torino, Italy
Background/Purpose: B-lymphocytes (BL) play a critical role in Systemic Lupus Erythematosus (SLE). BL depletion therapy still remains an attractive option, despite the disappointing results of…
Abstract Number: 1674 • 2014 ACR/ARHP Annual Meeting
Long-Term Efficacy of Rituximab in Systemic Sclerosis
Javier Narváez¹, Juan Jose Alegre Sancho², Ivan Castellvi³, Susana Herrera⁴, Maria Molina Molina⁵, Diego Castillo⁶, Isabel de la Morena Barrio², Montserrat Robustillo Villarino², Angels Martínez Ferrer², Desamparados Ybañez García², Elia Valls Pascual², Josep Maria LLobet³, Francisca Gil Latorre⁴ and Joan Miquel Nolla⁷, ¹Rheumatology, Hospital Universitario de Bellvitge. Barcelona. Spain, Barcelona, Spain, ²Rheumatology, Hospital Universitario Dr Peset, Valencia, Spain, ³Rheumatology, Hospital de Sant Pau, Barcelona, Spain, ⁴Hospital Universitario Dr Peset, Valencia, Spain, ⁵Pneumology, Hospital Universitario de Bellvitge, Barcelona, Spain, ⁶Pneumology, Hospital de Sant Pau, Barcelona, Spain, ⁷Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain
Background/Purpose: It has been proved in several studies with a small number of patients that Rituximab (RTX) can prevent worsening of interstitial lung disease (ILD)…
Abstract Number: 2782 • 2013 ACR/ARHP Annual Meeting
Retreatment With Rituximab In The Rituximab In ANCA-Associated Vasculitis (RAVE) Trial
Eli Miloslavsky¹, Ulrich Specks², Peter A Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke Unversity Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Retrospective studies have demonstrated that repeat rituximab treatment may be effective in re-inducing remission in relapsing ANCA-associated vasculitis. We analyzed data from the Rituximab…
Abstract Number: 2783 • 2013 ACR/ARHP Annual Meeting
Rituximab Versus Azathioprine For Maintenance In Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis: Follow Up At 39 Months
Benjamin Terrier¹, Christian Pagnoux², Alexandre Karras³, Chahera Khouatra⁴, Olivier Aumaître⁵, Pascal Cohen⁶, Francois Maurier⁷, Olivier Decaux⁸, Hélène Desmurs-Clavel⁹, Pierre Gobert¹⁰, Thomas Quemeneur¹¹, Claire Blanchard-Delaunay¹², Pascal Godmer¹³, Xavier Puéchal¹⁴, Luc Mouthon¹⁵ and Loic Guillevin¹⁶, ¹Internal Medicine, Cochin University Hospital, Paris, France, ²Division of Rheumatology, University of Toronto, Toronto, ON, Canada, ³Nephrology, Hôpital Européen Georges Pompidou, APHP, Paris, France, ⁴CHU Lyon, Lyon, France, ⁵Division of internal Medicine, Centre Hospitalier Universitaire, Hôpital Gabriel Montpied, Clermont–Ferrand, Clermont–Ferrand, France, ⁶National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, Paris, France, ⁷HP Metz Belle Isle Hospital, Department of Internal Medicine, Metz, France, ⁸Department of Internal Medicine, Rennes University Hospital, Rennes, France, ⁹Internal Medicine, Hospices Civils de Lyon, Hôpital Louis Pradel, Lyon, France, ¹⁰Nephrology, Centre Hospitalier d'Avignon, Avignon, France, ¹¹Internal medicine, CHR de Valenciennes, Valenciennes, France, ¹²Internal Medicine, Hôpital de Niort, Niort, France, ¹³Department of Internal Medicine, Centre Hospitalier Bretagne Atlantique de Vannes, Vannes, France, ¹⁴National Referral Center for Rare Systemic Auto-immune Diseases, Hôpital Cochin, AP-HP, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ¹⁵Department of Internal Medicine, Referral Center for Rare Autoimmune and Systemic Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, Paris, France, ¹⁶Internal Medicine, Hôpital Cochin, University Paris Descartes, Paris, France
Rituximab Versus Azathioprine for Maintenance in Antineutrophil Cytoplasmic Antibodies-Associated Vasculitis: Follow up at 39 months.Background/Purpose: Rituximab was shown to be as effective as cyclophosphamide to…
Abstract Number: 742 • 2013 ACR/ARHP Annual Meeting
Safety Of Remission Induction With Rituximab Versus Cyclosphosphamide In Patients 65 and Older With Severe ANCA-Associated Vasculitis
Eli Miloslavsky¹, Ulrich Specks², Peter A Merkel³, Philip Seo⁴, Robert F. Spiera⁵, Carol A. Langford⁶, Gary S. Hoffman⁷, Cees G.M. Kallenberg⁸, E. William St. Clair⁹, Nadia Tchao¹⁰, Linna Ding¹¹, David Ikle¹², Brett Jepson¹², Paul Brunetta¹³ and John H. Stone¹⁴, ¹Division of Rheumatology, Massachusetts General Hopsital, Boston, MA, ²Mayo Clinic, Rochester, MN, ³Division of Rheumatology, University of Pennsylvania and VA Medical Center, Philadelphia, PA, ⁴Rheumatology Division, Johns Hopkins Vasculitis Center, Johns Hopkins University, Baltimore, MD, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Center for Vasculitis Care and Research, Cleveland Clinic, Cleveland, OH, ⁷Center for Vasculitis Care and Research, Cleveland Clinic Foundation, Cleveland, OH, ⁸Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, Netherlands, ⁹Medicine, Duke University Medical Center, Durham, NC, ¹⁰Immune Tolerance Network, Bethesda, MD, ¹¹NIAID, Bethesda, MD, ¹²Rho, Chapel Hill, NC, ¹³Biotherapeutics, Genentech, So San Francisco, CA, ¹⁴Rheumatology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Retrospective studies have demonstrated that patients of advanced age with systemic vasculitis experience a higher mortality and adverse events than their younger counterparts. However,…
Abstract Number: 2153 • 2012 ACR/ARHP Annual Meeting
Target-Directed Development of a Proposed Biosimilar Rituximab (GP2013): Comparability of Antibody-Dependent Cellular Cytotoxicity Activity and Pre-Clinical Pharmacokinetics and Pharmacodynamics with Originator Rituximab
Antonio da Silva¹, Ulrich Kronthaler¹, Ines Meyer¹, Anastassia Papandrikopoulou², Thomas Stangler¹ and Jan Marinus Visser¹, ¹Preclinical Development, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany, ²Medical Communications, Sandoz Biopharmaceuticals / HEXAL AG, Holzkirchen, Germany
Background/Purpose: Biosimilars are biologics approved by highly-regulated markets as similar to existing agents, with the aim of offering more affordable treatment and thereby increasing patient…
Abstract Number: 1927 • 2012 ACR/ARHP Annual Meeting
Inflammatory Meningeal Involvement in Patients with Rheumatic Diseases Responsive to Rituximab
Jane Park¹, Eyal Kedar¹, Ingeborg Sacksen¹, John Henson² and Gregory C. Gardner³, ¹Rheumatology, University of Washington, Seattle, WA, ²Neurology, Swedish Neuroscience Institute, Seattle, WA, ³Medicine/Rheumatology, University of Washington, Seattle, WA
Background/Purpose: Inflammatory meningeal involvement can be idiopathic or associated with a variety of inflammatory rheumatic diseases such as ANCA associated vasculitis (AAV), rheumatoid (RA) arthritis,…
Abstract Number: 1694 • 2012 ACR/ARHP Annual Meeting
Infection Risk in Patients with Low Immunoglobulins Following Rituximab Treatment in Rheumatoid Arthritis
Ronald F. van Vollenhoven¹, Gregg J. Silverman², Clifton O. Bingham III³, Patrick Durez⁴, Patrica B. Lehane⁵, Nicola Tyson⁵ and Elena Fisheleva⁵, ¹Karolinska University Hospital, Stockholm, Sweden, ²Medical and Pathology, NYU School of Medicine, New York, NY, ³Department of Medicine, Johns Hopkins University, Baltimore, MD, ⁴University Hospital St Luc, UCL, Brussels, Belgium, ⁵Roche Products Limited, Welwyn Garden City, United Kingdom
Background/Purpose: This study analyzed infection rates in patients (pts) with low immunoglobulin (Ig) serum concentrations following rituximab (RTX) treatment in RA clinical trials. Methods: Pooled…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].